Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by DiaMedica Therapeutics Inc. < Previous 1 2 Next > DiaMedica Therapeutics Upcoming Conference Participation September 04, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results August 07, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 August 01, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia July 11, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement July 01, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces $11.8 Million Private Placement June 26, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia June 26, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results May 08, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 May 02, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke April 17, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results March 19, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference January 29, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer January 22, 2024 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results November 13, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 November 09, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 November 06, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer September 12, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference September 06, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results August 14, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 August 08, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference July 18, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement June 26, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces $37.5 Million Private Placement June 21, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke June 21, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors May 30, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results May 15, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 May 08, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer April 11, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results March 28, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 March 20, 2023 From DiaMedica Therapeutics Inc. Via Business Wire Tickers DMAC < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.